[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356441-105":59,"doc-detail-356441-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","disparities-in-adverse-event-perception-between-patients-and-healthcare-providers-in-gynaecologic-anticancer-therapy-observational-web-based-study-in-japan","Disparities in adverse event perception between patients and healthcare providers in gynaecologic anticancer therapy - observational web-based study in Japan","","Objective explores how patients receiving anticancer drugs for gynaecological cancer perceive and manage adverse events (AEs), particularly AEs they want to avoid, dose adjustment views, and communication with healthcare professionals. An observational web-based questionnaire enrolled Japanese chemotherapy patients and related healthcare professionals. Outcomes include desired avoidant AEs, pre-/post-treatment perception differences, patient-provider communication discrepancies, distress from visit timing, and awareness of dose adjustment to suppress AEs. Findings show discordant AE severity ratings and varied symptom reporting patterns, with visit and administration timing influencing distress.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/disparities-in-adverse-event-perception-between-patients-and-healthcare-providers-in-gynaecologic-anticancer-therapy-observational-web-based-study-in-japan/356441/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/disparities-in-adverse-event-perception-between-patients-and-healthcare-providers-in-gynaecologic-anticancer-therapy-observational-web-based-study-in-japan/356441.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s primary objective?","Question",{"text":112,"@type":113},"To explore patients’ perceptions of managing adverse events from anticancer drugs for gynaecological cancer, including AEs they want to avoid, views on dose adjustments, and communication with healthcare professionals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and who participated?",{"text":117,"@type":113},"It was an observational study using a web-based questionnaire. Women in Japan who had received chemotherapy for endometrial or ovarian/fallopian tube cancer were enrolled, along with healthcare professionals such as obstetrics and gynaecology physicians, nurses, and pharmacists who administered chemotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What key discrepancies were found between patients and healthcare professionals?",{"text":121,"@type":113},"Patients and healthcare professionals differed in which AEs were most distressing and in symptom communication. For example, physicians rated nausea/vomiting lower and alopecia higher than patients, pharmacists emphasized peripheral neuropathy, and younger patients tended to communicate fewer symptoms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356441,1790344199,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Open access Original research  \n Disparities in adverse event perception  \nbetween patients and healthcare providers in gynaecologic anticancer therapy: results from an observational web-based study in Japan  \nHironobu Hashimoto,1 Azusa Soejima,2 Yumiko Nishimura,3 Ami Ike,4 Michiko Sugawara,4 Muneaki Shimada,5,6 Masakazu Abe  7  \nTo cite: Hashimoto H, Soejima A, Nishimura Y, et al. Disparities in adverse event perception between patients and healthcare providers in gynaecologic anticancer therapy: results from an observational web-based study in Japan. BMJ Open 2026;16:e107743 . doi:10 . 1136/ bmjopen-2025-107743  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2025-107743](bmjopen-2025-107743)) .  \nReceived 10 July 2025 Accepted 06 February 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Masakazu Abe;  \n[ma.abe@hama-med.ac.jp](ma.abe@hama-med.ac.jp)  \nABSTRACT  \nObjective To explore patients’ perceptions of managing adverse events (AEs) from anticancer drugs for gynaecological cancer, focusing on AEs they want to avoid, views on dose adjustments and communication with healthcare professionals.  \nDesign Observational study using a web-based questionnaire.  \nParticipants Women in Japan who had received chemotherapy for endometrial or ovarian/fallopian tube cancer were enrolled. Healthcare professionals, including obstetrics and gynaecology physicians, nurses and pharmacists, who administered chemotherapy to these patients, were also enrolled.  \nOutcome measures AEs that patients wished to avoid or found distressing; varied perceptions of AEs before and after treatment; discrepancies in the communication of AEs between patients and healthcare professionals; administration time and intervals between hospital visits patients found distressing; patient awareness of dose adjustment (reduction, interruption or discontinuation) to suppress AEs.  \nResults Participants comprised 153 physicians, 166 nurses, 154 pharmacists and 154 patients. Nausea/ vomiting (28.6%), alopecia (18.2%) and peripheral neuropathy (9 . 1%) were the most distressing AEs overall. Physicians rated nausea/vomiting lower (15 .4%) and alopecia higher (38 .2%) than patients, while pharmacists emphasised peripheral neuropathy (25 .7%) . Many patients found AEs, including peripheral neuropathy (53/99), fatigue (52/105) and alopecia (46/120), to be more severe than expected. Communication patterns revealed that 49 .4% of patients reported all symptoms, even uncertain ones, but younger patients tended to communicate fewer symptoms. Physicians (54 .2%), nurses (92 .2%) and pharmacists (85 .7%) preferred full disclosure of symptoms. While 28.6% of patients wished to avoid dose reductions because of fears of disease progression, 18 .2% preferred dose reduction or discontinuation when AEs became intolerable. Drug administration times and visit intervals influenced patient distress. Treatment administration of over 3 hours (19 .5%) and visits occurring more frequently than once every 3 weeks (27 .3%) were the most distressing.  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ The inclusion of both patients and healthcare professionals (physicians, nurses and pharmacists) enabled a comprehensive analysis of adverse event perceptions and communication dynamics.  \n⇒ The web-based survey facilitated access to a diverse participant pool across various treatment stages and cancer types.  \n⇒ The cross-sectional design limits the ability to assess changes in perceptions or communication overtime and prevents causal inferences.  \n⇒ Because of the use of self-reported data, this study is susceptible to recall bias and ","cbCaibwY3bNxpPEH","https://ap.wps.com/l/cbCaibwY3bNxpPEH","pdf",1421279,"English","# Abstract\n## Objective\n## Design\n## Participants\n## Outcome measures\n## Results\n## Strengths and limitations\n## Conclusions\n# Introduction","[{\"question\":\"What was the study’s primary objective?\",\"answer\":\"To explore patients’ perceptions of managing adverse events from anticancer drugs for gynaecological cancer, including AEs they want to avoid, views on dose adjustments, and communication with healthcare professionals.\"},{\"question\":\"How was the study conducted and who participated?\",\"answer\":\"It was an observational study using a web-based questionnaire. Women in Japan who had received chemotherapy for endometrial or ovarian/fallopian tube cancer were enrolled, along with healthcare professionals such as obstetrics and gynaecology physicians, nurses, and pharmacists who administered chemotherapy.\"},{\"question\":\"What key discrepancies were found between patients and healthcare professionals?\",\"answer\":\"Patients and healthcare professionals differed in which AEs were most distressing and in symptom communication. For example, physicians rated nausea/vomiting lower and alopecia higher than patients, pharmacists emphasized peripheral neuropathy, and younger patients tended to communicate fewer symptoms.\"}]","Disparities in adverse event perception between patients and healthcare providers in gynaecologic anticancer therapy - observational web-based study in Japan | PDF",1790125341,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8182bc89452886014590ee9efa75a2cd.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/843b0770d84da3ffa894ae085ed3f5c1.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12fd2c3c108b6aa823f81cade3aa4c4b.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd878cd8a2d57a045f0d2b426e35d4c8.webp",980,1306]